Participated in Alveus Therapeutics' $160M Series A for next-generation obesity and metabolic disease therapies.
Alveus Therapeutics is focused on developing next-generation metabolic therapies aimed at sustainable weight loss and improved patient outcomes in the obesity treatment landscape
Alveus Therapeutics is focused on developing next-generation metabolic therapies aimed at sustainable weight loss and improved patient outcomes in the obesity treatment landscape.